What Is the Best Time to Take Antihypertensives?

Bedtime hypertensive therapy might reduce the risk of cardiovascular events according to this study soon to be published in Eur Heart J. However, despite showing significant risk reduction this hypothesis calls for further study before radically changing the usual upon awakening therapy. 

¿Cuál es el mejor momento del día para administrar antihipertensivos?

Taking the prescribed medication before bedtime could allow our bodies to naturally follow its circadian rhythms, boosting medication effect, improving blood pressure control and, ultimately, reducing cardiovascular events. 

This study is, without question, the largest to assess blood pressure medication time intake and the one with longest follow-up. It was carried out in several primary healthcare centers and, therefore, should reflect the daily practice. 

The Hygia Chronotherapy Trial randomized over 19000 hypertensive patients to taking medication upon awakening (angiotensin blockers, angiotensin converting enzyme inhibitors, calcium blockers, beta blockers and/or diuretics) vs. at bedtime. 


Read also: Prosthesis Mismatch in Supra and Intra Annular valves.


After a mean 6.3-year follow-up, patients taking their medication before going to bed had better systolic and diastolic blood pressure control.

In addition, a much smaller group of patients taking medication at bedtime qualified as “nondippers” (when blood pressure drops less than 10% while sleeping) vs. morning intake (37% vs 50%, p=0.001).

Finally, and most importantly, bedtime therapy reduced 45% primary end point risk, a composite of cardiovascular death, acute MI, coronary revascularization, cardiac failure and any stroke (p<0.001).

Some of the study data raises questions about the fact that bedtime therapy did not change daytime blood pressure readings vs. morning therapy.



Read also: Subintimal vs. Intraplaque Coronary Rechanneling. Do Results Vary?


For some experts, it seems hard to explain why reducing blood pressure while sleeping translates in such a significant reduction in events. One possible explanation, that requires validation, is that reducing blood pressure during sleep-time might have a pleiotropic effect that exceeds reduction readings per se. 

Original title: Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.

Reference: Hermida RC et al. Eur Heart J. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...